Editas Medicine, Inc. (EDIT)

Editas Medicine, Inc.'s Q·Score is 4.2/10 (Bearish), reflecting its current fundamentals, analyst data, and valuation metrics. Consensus analyst target of $5.78 is 118% above current price. Key area to monitor: currently unprofitable (-282% margin). This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.

The consensus price target for EDIT is $5.78, based on ratings from 9 Wall Street analysts. This is 118.4% above the current price of $2.65. Price targets are forward-looking estimates and not guarantees of future performance.

Editas Medicine, Inc. (EDIT) scores in line with sector averages on valuation metrics. The consensus analyst price target of $5.78 is 118% above the current price.

Editas Medicine, Inc. has a net profit margin of -281.6%, indicating the company is currently operating at a net loss. Its gross margin stands at -109.2%, reflecting a more cost-intensive business model.

Editas Medicine, Inc. is reporting revenue declining 39.2% year-over-year.

Editas Medicine, Inc. has a debt-to-equity ratio of 3.92×, reflecting a high debt-to-equity ratio, which increases financial risk especially in rising rate environments. Its current ratio is 3.22×, indicating comfortable short-term liquidity.